Evidence map›Paper›PMID 26587992›Full record

ArticlePloS one2015

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.

Peng Ye, Meizhuo Zhang, Shuqiong Fan, Tianwei Zhang, Haihua Fu, Xinying Su, Paul R Gavine, Qiang Liu, Xiaolu Yin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Latest development of liquid biopsy.Journal of thoracic disease · 2018
    Review
  11. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Perspectives of HER2-targeting in gastric and esophageal cancer.Expert opinion on investigational drugs · 2017
    Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Peng YeAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Meizhuo ZhangResearch & Development Information, AstraZeneca R&D, Shanghai, China.
Shuqiong FanAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Tianwei ZhangAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Haihua FuAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Xinying SuAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Paul R GavineAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Qiang LiuDepartment of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaolu YinAsia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Renji Hospital · CNShanghai Medical Information Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current drug development efforts on gastric cancer are directed against several molecular targets driving the growth of this neoplasm. Intra-tumoral biomarker heterogeneity however, commonly observed in gastric cancer, could lead to biased selection of patients. MET, ATM, FGFR2, and HER2 were profiled on gastric cancer biopsy samples. An innovative pathological assessment was performed through scoring of individual biopsies against whole biopsies from a single patient to enable heterogeneity evaluation. Following this, false negative risks for each biomarker were estimated in silico. 166 gastric cancer cases with multiple biopsies from single patients were collected from Shanghai Renji Hospital. Following pre-set criteria, 56 ~ 78% cases showed low, 15 ~ 35% showed medium and 0 ~ 11% showed high heterogeneity within the biomarkers profiled. If 3 biopsies were collected from a single patient, the false negative risk for detection of the biomarkers was close to 5% (exception for FGFR2: 12.2%). When 6 biopsies were collected, the false negative risk approached 0%. Our study demonstrates the benefit of multiple biopsy sampling when considering personalized healthcare biomarker strategy, and provides an example to address the challenge of intra-tumoral biomarker heterogeneity using alternative pathological assessment and statistical methods.

Indexed as

Ataxia Telangiectasia Mutated ProteinsBiomarkers, TumorBiopsyErb-b2 Receptor Tyrosine KinasesFalse Negative ReactionsGene AmplificationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescencePrecision MedicineProto-Oncogene Proteins c-metReceptor, Fibroblast Growth Factor, Type 2Risk AssessmentStomach NeoplasmsAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR2 protein, humanMET protein, humanProto-Oncogene Proteins c-metReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID26587992
PMCPMC4654477
OpenAlexW2178670888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.